Novel B7-H3 ADC ICP-B794’s Preclinical Data Unveiled at 2026 AACR, Demonstrating Superior Anti-Tumor Activity and Safety

(SeaPRwire) –   BEIJING, April 21, 2026 — InnoCare Pharma (HKEX: 9969; SSE: 688428) unveiled preclinical findings for its novel B7-H3 targeted antibody-drug conjugate (ADC), ICP-B794, at the 2026 American Association for Cancer Research (AACR) Annual Meeting.

The data was shared via a poster presentation (Abstract Code: LB355) at the meeting. ICP-B794 is an ADC targeting B7-H3 that features a novel linker-payload configuration. In preclinical tumor models, it showed strong anti-tumor efficacy and a substantially wider safety margin than comparable therapies. A Phase I clinical trial to determine the appropriate dosage is currently in progress.

ADCs are often described as “biological missiles” for their precision in targeting cancer cells. Developed from InnoCare’s proprietary ADC platform, ICP-B794 utilizes an irreversible connector, a highly hydrophilic linker, and a novel, potent payload. This combination leads to markedly improved tumor-killing capabilities, along with greater stability and safety.

The candidate demonstrated excellent stability in its drug-to-antibody ratio (DAR) and minimal payload release in human plasma. In in vitro cellular tests, ICP-B794’s cell-killing activity was significantly greater than that of similar drugs. It also showed superior in vivo effectiveness compared to other B7-H3 ADCs, producing therapeutic results even at low doses. A key finding is its potential to overcome resistance associated with other B7-H3 targeted ADCs.

Safety assessments yielded highly positive results from the GLP toxicology study, indicating a safety window greater than 200-fold.

About InnoCare

InnoCare is a commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing first-in-class and/or best-in-class therapies for cancer and autoimmune diseases to address significant unmet medical needs in China and globally. The company has operations in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States.

InnoCare Forward-looking Statements

This press release includes certain forward-looking statements. Any statements that are not historical facts may be considered forward-looking, relating to our or our management’s future intentions, plans, beliefs, or expectations. These statements represent assumptions and estimates made by management based on their experience, knowledge of historical trends, current conditions, expected future developments, and other relevant factors. Forward-looking statements are not guarantees of future performance, and actual results, developments, and business decisions may differ from those projected. These statements are also subject to numerous risks and uncertainties that could impact the company’s performance in both the short and long term.

Contact

Media	Investors
Chunhua Lu
86-10-66609879	86-10-66609999
chunhua.lu@innocarepharma.com	ir@innocarepharma.com